J&J | JNJ - Fremdkapital





Fremdkapital Veränderung Datum
AbbVie USD 64.53B 5.59B 2026-03
Abbott USD 29.64B 19.74B 2026-03
Amgen USD 51.86B 27M 2026-06
AstraZeneca USD 26.01B 46M 2026-06
Baxter International USD 8.62B 6M 2026-06
Bayer EUR 31.16B 480M 2026-06
Becton, Dickinson and Co. USD 13.51B 1.2B 2026-06
Biogen USD 7.29B 1B 2026-06
Boston Scientific USD 10.86B 148M 2026-03
Bristol-Myers Squibb USD 42.09B 59M 2026-06
CONMED USD 657.05M 203.11M 2026-06
Cooper Companies USD 1.92B 54.8M 2026-06
Dexcom USD 1.3B 200K 2026-06
Edwards Lifesciences USD 598.7M 1.3M 2026-06
Eli Lilly USD 47.86B 8.49B 2026-06
Gilead Sciences USD 20.86B 1.27B 2026-03
GlaxoSmithKline GBP 13.95B 65M 2026-06
Globus Medical USD 398K 38K 2026-03
Insulet USD 929.5M 0 2026-06
Integra LifeSciences USD 1.83B 2.05M 2026-06
Intuitive Surgical USD 0 0 2025-03
J&J USD 37.34B 183M 2026-06
Medtronic USD 25.62B 502M 2026-06
Merck USD 51.08B 4.41B 2026-06
Merit Medical Systems USD 736.26M 1.1M 2026-06
Novartis USD 37.49B 42M 2026-06
Pfizer USD 60.5B 70M 2026-06
Regeneron Pharmaceuticals USD 1.99B 400K 2026-06
Roche Holding CHF 25.22B 2.21B 2026-06
Sanofi EUR 14.65B 806M 2026-06
Stryker USD 14.19B 32M 2026-06
Tandem Diabetes Care USD 602.58M 809K 2026-06
Teva Pharmaceutical Industries USD 12.09B 1.92B 2026-06
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12
Zimmer Biomet Holdings USD 6.28B 17.6M 2026-06
Zoetis USD 9.05B 3M 2026-06